- SEK125.80m
- SEK123.22m
- SEK32.20m
- 39
- 10
- 56
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 1.91 | ||
| PEG Ratio (f) | 0.03 | ||
| EPS Growth (f) | 290.02% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.57 | ||
| Price to Tang. Book | 7.9 | ||
| Price to Free Cashflow | 105.63 | ||
| Price to Sales | 3.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.33% | ||
| Return on Equity | -1.34% | ||
| Operating Margin | -18.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 6.33 | 10.69 | 24.89 | 39.85 | 32.2 | 399 | 607 | 43.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +65.15 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medclair AB, formerly known as Medclair Invest AB, is a Sweden-based company primarily engaged in research and development. The Company’s scope of activities revolves around measurement, collection, and destruction of Nitrous Oxide (N2O). What is more, the Company is specialized in catalytic gas purification as well as is involved in processes that are related to gas purification and gas measurement, ventilation, and control. Given the Firm’s operations associated with Nitrous Oxide, which can serve the purpose of a short-acting sedative, its customers mainly comprise of establishments active in the healthcare industry, which include maternity wards, children’s healthcare facilities, as well as dental care facilities.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 24th, 2005
- Public Since
- March 3rd, 2017
- No. of Employees
- 14
- Sector
- Machinery, Equipment & Components
- Industry
- Industrials
- Exchange
Nordic Growth Market - Stockholm- Shares in Issue
- 82,492,057
- Address
- Box 3113, STOCKHOLM, 103 62
- Web
- https://www.medclair.com/
- Phone
- +46 24319090
- Auditors
- Allians Auditeurs & Associes
Upcoming Events for MCLR
Similar to MCLR
Abelco Investment AB
Nordic Growth Market - Stockholm
Frontwalker AB (publ)
Nordic Growth Market - Stockholm
Hybricon AB
Nordic Growth Market - Stockholm
Rentunder Holding AB
Nordic Growth Market - Stockholm
Sarsys AB
Nordic Growth Market - Stockholm
FAQ
As of Today at 21:58 UTC, shares in Medclair AB are trading at SEK1.53. This share price information is delayed by 15 minutes.
Shares in Medclair AB last closed at SEK1.53 and the price had moved by +17.76% over the past 365 days. In terms of relative price strength the Medclair AB share price has outperformed the FTSE Global All Cap Index by +14.81% over the past year.
There is no consensus recommendation for this security.
Find out moreMedclair AB does not currently pay a dividend.
Medclair AB does not currently pay a dividend.
Medclair AB does not currently pay a dividend.
To buy shares in Medclair AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK1.53, shares in Medclair AB had a market capitalisation of SEK125.80m.
Here are the trading details for Medclair AB:
- Country of listing: Sweden
- Exchange: NGM
- Ticker Symbol: MCLR
Based on an overall assessment of its quality, value and momentum Medclair AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medclair AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -6.85%.
As of the last closing price of SEK1.53, shares in Medclair AB were trading -2.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medclair AB PE ratio based on its reported earnings over the past 12 months is 1.91. The shares last closed at SEK1.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medclair AB's management team is headed by:
- Christer Sjolund - CHM
- Peter Evertsson - CEO
- Roro Yakoub - FDR